Can cabozantinib rescue liver cancer patients after immunotherapy fails?
Disease control
Ongoing
This study tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. Participants take a daily pill, and researchers track side effects and …
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated May 17, 2026 08:46 UTC